Tearsheet

Firefly Neuroscience (AIFF)

Market Price (12/24/2025): $1.19 | Market Cap: $16.1 Mil
Sector: Information Technology | Industry: Application Software

Firefly Neuroscience (AIFF)

Market Price (12/24/2025): $1.19
Market Cap: $16.1 Mil
Sector: Information Technology
Industry: Application Software

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%	Weak multi-year price returns 2Y Excs Rtn is -122%, 3Y Excs Rtn is -174%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1119%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 958%		Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 106%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -972%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -985%
3	Megatrend and thematic drivers Megatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics.		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -147%
4			High stock price volatility Vol 12M is 215%
5			Key risks AIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 958%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77%
3	Megatrend and thematic drivers Megatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics.
4	Weak multi-year price returns 2Y Excs Rtn is -122%, 3Y Excs Rtn is -174%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1119%
6	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 106%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -972%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -985%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -147%
9	High stock price volatility Vol 12M is 215%
10	Key risks AIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more.

Valuation, Metrics & Events

	12/24/25	2024	2023	2022	2021
Share Price CYE	$1.19	$2.65	$5.07	$14.40	$148.50
Market Cap CYE ($ Mil)	16.1	23.1	26.3	74.8	1,881.3
Total Debt ($ Mil)	0.0	0.7	0.0	0.0	1.8
Total Cash ($ Mil)	4.3	1.8	2.1	0.1	0.7
Enterprise Value ($ Mil)	11.7	23.8	26.3	74.8	1,883.1
Valuation Ratios
P/S TTM	20.5	160.6	52.9	-	24,106.5
P/EBIT TTM	-0.8	-1.7	-10.2	-23.3	-181.7
P/E TTM	-0.8	-1.7	-10.1	-19.7	-176.1
P/FCF TTM	-2.1	-2.6	-10.3	-25.9	-201.9
Sector Ratios
P/S TTM (Sector)	3.2	3.2	2.9	2.6	4.6
P/EBIT TTM (Sector)	3.1	2.3	-0.2	-0.7	-0.0
P/E TTM (Sector)	-0.2	-0.3	-0.5	-0.8	-0.0
P/FCF TTM (Sector)	12.5	13.7	12.2	6.9	13.8

	12/24/25	2024	2023
Share Price CYE	$1.19	$2.65	$5.07
Market Cap CYE ($ Mil)	16.1	23.1	26.3
Total Debt ($ Mil)	0.0	0.7	0.0
Total Cash ($ Mil)	4.3	1.8	2.1
Enterprise Value ($ Mil)	11.7	23.8	26.3
Valuation Ratios
P/S TTM	20.5	160.6	52.9
P/EBIT TTM	-0.8	-1.7	-10.2
P/E TTM	-0.8	-1.7	-10.1
P/FCF TTM	-2.1	-2.6	-10.3
Sector Ratios
P/S TTM (Sector)	3.2	3.2	2.9
P/EBIT TTM (Sector)	3.1	2.3	-0.2
P/E TTM (Sector)	-0.2	-0.3	-0.5
P/FCF TTM (Sector)	12.5	13.7	12.2

	AIFF	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	1,075.8%	7.3%
Rev Chg LTM	958.1%	6.1%
Rev Chg 3Y Avg	958.1%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-1,119.4%	18.8%
CFO/Rev LTM	-971.5%	20.4%
Net Inc Mgn	-2,705.9%	13.1%
VALUATION	VERY HIGH
P/S	19.1	3.2
P/CFO	-2.0	15.7
P/FCF	-1.9	20.6
P/E	-0.7	23.5
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.35	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Granted Patents	27	5052025	Link
Number of Commercial Users	60	5052025	Link
Proprietary EEG/ERP Database Size	over 180,000 standardized EEG/ERP assessment records	5052025	Link

null

AIFF Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

From approximately August 31, 2025, to December 25, 2025, Firefly Neuroscience (AIFF) experienced a significant stock decline of around 58.5%, attributed to several key factors.

1. Continued Net Losses and Cautious Financial Outlook: Despite reporting substantial revenue growth in the third quarter of 2025, primarily due to the acquisition of Evoke Neuroscience, Firefly Neuroscience continued to report net losses, with a net loss of $2.6 million for Q3 2025. This indicated ongoing challenges in achieving profitability, which likely contributed to investor skepticism.

2. Bearish Analyst Ratings and Negative Price Forecasts: Throughout this period, Firefly Neuroscience received unfavorable assessments from analysts and technical indicators. By December 2025, StockInvest.us downgraded the stock to a "Strong Sell" candidate, predicting a further fall of approximately 53% in the subsequent three months.

Show more From approximately August 31, 2025, to December 25, 2025, Firefly Neuroscience (AIFF) experienced a significant stock decline of around 58.5%, attributed to several key factors.

1. Continued Net Losses and Cautious Financial Outlook: Despite reporting substantial revenue growth in the third quarter of 2025, primarily due to the acquisition of Evoke Neuroscience, Firefly Neuroscience continued to report net losses, with a net loss of $2.6 million for Q3 2025. This indicated ongoing challenges in achieving profitability, which likely contributed to investor skepticism.

2. Bearish Analyst Ratings and Negative Price Forecasts: Throughout this period, Firefly Neuroscience received unfavorable assessments from analysts and technical indicators. By December 2025, StockInvest.us downgraded the stock to a "Strong Sell" candidate, predicting a further fall of approximately 53% in the subsequent three months.

3. Negative Technical Signals and High Stock Volatility: The company's stock exhibited strong bearish technical signals, including "sell" signals from both short-term and long-term moving averages, indicating a negative trend. High stock volatility was also observed, with significant daily and weekly price decreases, notably a 31.61% decline over 10 days in December 2025.

4. Announcement of a Shareholder Investigation: On October 9, 2025, a shareholder investigation into Firefly Neuroscience, Inc. by Purcell & Lefkowitz LLP was announced, which typically creates negative sentiment and concern among investors, potentially impacting the stock price.

5. Inability of Positive Operational News to Counteract Negative Trends: While the company made several positive operational announcements during the period, such as the successful deployment of its NVIDIA-powered 'CLEAR' platform in August 2025 and new partnerships in September 2025, these developments were seemingly insufficient to outweigh the persistent financial concerns and bearish market sentiment, leading to an overall significant stock depreciation. Show less

Stock Movement Drivers

Fundamental Drivers

The -62.4% change in AIFF stock from 9/24/2025 to 12/24/2025 was primarily driven by a -78.1% change in the company's P/S Multiple.

	9242025	12242025	Change
Stock Price ($)	2.95	1.11	-62.37%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.43	0.78	82.94%
P/S Multiple	87.32	19.13	-78.09%
Shares Outstanding (Mil)	12.67	13.50	-6.54%
Cumulative Contribution			-62.53%

LTM = Last Twelve Months as of date shown

Market Drivers

9/24/2025 to 12/24/2025

	Return	Correlation
AIFF	-62.7%
Market (SPY)	4.4%	44.5%
Sector (XLK)	5.1%	44.0%

Fundamental Drivers

The -60.6% change in AIFF stock from 6/25/2025 to 12/24/2025 was primarily driven by a -159.8% change in the company's Shares Outstanding (Mil).

	6252025	12242025	Change
Stock Price ($)	2.82	1.11	-60.64%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2.08	0.78	-62.33%
P/S Multiple	7.05	19.13	171.51%
Shares Outstanding (Mil)	5.19	13.50	-159.84%
Cumulative Contribution			-161.20%

LTM = Last Twelve Months as of date shown

Market Drivers

6/25/2025 to 12/24/2025

	Return	Correlation
AIFF	-61.0%
Market (SPY)	14.0%	40.8%
Sector (XLK)	17.5%	38.4%

Fundamental Drivers

The -56.3% change in AIFF stock from 12/24/2024 to 12/24/2025 was primarily driven by a -92.1% change in the company's P/S Multiple.

	12242024	12242025	Change
Stock Price ($)	2.54	1.11	-56.30%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.07	0.78	958.11%
P/S Multiple	243.05	19.13	-92.13%
Shares Outstanding (Mil)	7.08	13.50	-90.62%
Cumulative Contribution			-92.19%

LTM = Last Twelve Months as of date shown

Market Drivers

12/24/2024 to 12/24/2025

	Return	Correlation
AIFF	-56.7%
Market (SPY)	15.8%	15.4%
Sector (XLK)	22.2%	14.8%

Fundamental Drivers

null
null

Market Drivers

12/25/2023 to 12/24/2025

	Return	Correlation
AIFF	-77.0%
Market (SPY)	48.9%	13.3%
Sector (XLK)	54.1%	10.8%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
AIFF Return	996%	241%	-90%	-65%	-48%	-55%	-70%
Peers Return	�	�	�	�	�	8%	�
S&P 500 Return	16%	27%	-19%	24%	23%	18%	115%
Monthly Win Rates [3]
AIFF Win Rate	50%	58%	17%	42%	42%	25%
Peers Win Rate	�	�	�	�	45%	42%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
AIFF Max Drawdown	-32%	-15%	-92%	-74%	-54%	-55%
Peers Max Drawdown	�	�	�	�	�	-36%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: CBLL, NMTC, STIM, NPCE, LIVN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

Unique Key	Event	AIFF	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-97.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	4542.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-54.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	119.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	80 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-79.5%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	387.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	292 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-91.7%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	1100.0%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	247 days	1,480 days

Compare to ADSK, HIT, BMR, BTTC, CCC

In The Past

Firefly Neuroscience's stock fell -97.8% during the 2022 Inflation Shock from a high on 3/28/2022. A -97.8% loss requires a 4542.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Firefly Neuroscience (AIFF)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.

AI Analysis | Feedback

Here are 1-3 brief analogies for Firefly Neuroscience (AIFF):

Essentially, the 23andMe for your brain's electrical activity, using AI to provide objective insights into neurological and psychiatric conditions.
Think of them as the LabCorp for brain health, but instead of blood tests, they use AI to analyze brainwaves (EEG) for diagnostic insights.
They are like the Palantir for neurological data, applying AI to uncover diagnostic patterns from complex brain signals.

AI Analysis | Feedback

Firefly Dx System / Brain Function Assessment Platform: This comprehensive diagnostic platform combines specialized EEG hardware with AI-powered software and cloud analytics to provide objective physiological biomarkers of brain function for the diagnosis and monitoring of neurological and psychiatric disorders.

AI Analysis | Feedback

Firefly Neuroscience (AIFF) primarily sells its advanced EEG-based diagnostic and brain health systems to other companies and organizations within the healthcare and research sectors.

While specific individual "major customers" (e.g., a single hospital system or clinic chain) are typically not disclosed in their public filings due to the distributed nature of medical device and diagnostic sales, their primary customer categories include:

Hospitals and Hospital Systems: Healthcare organizations ranging from large academic medical centers to community hospitals that integrate advanced neurological and psychiatric diagnostics into their patient care services. These systems often consist of various public, private, and non-profit entities.
Neurology and Psychiatry Clinics: Specialized outpatient clinics and private practices focused on diagnosing and treating brain health conditions, mental health disorders, and neurological illnesses.
Research Institutions and Academic Medical Centers: Universities and dedicated research facilities that utilize Firefly Neuroscience's technology for clinical trials, scientific studies, and advanced patient care integration and development.

Firefly Neuroscience's sales model is focused on widespread adoption across these institutional categories rather than reliance on a small number of named, publicly traded "major customers" that account for a significant portion of their revenue.

AI Analysis | Feedback

null

AI Analysis | Feedback

Greg Lipschitz, Chief Executive Officer

Greg Lipschitz was appointed Chief Executive Officer in January 2025, having previously served as Interim Chief Executive Officer and Executive Chairman. He has over 14 years of experience in private equity, capital markets, and merchant banking, and has advised on over $1 billion in mergers and acquisitions. Lipschitz has been a member of the company's board since 2022.

Paul Krzywicki, Chief Financial Officer & Company Secretary

Paul Krzywicki was appointed Chief Financial Officer in March 2024. He brings over 15 years of experience in finance and operations. Krzywicki's employment agreement was amended to increase his annual salary effective September 1, 2025, and he has received stock options and restricted stock units under the company's 2024 Long-Term Incentive Plan.

David DeCaprio, President & Chief Operating Officer

David DeCaprio is the President and Chief Operating Officer of Firefly Neuroscience. He is also a co-founder of ClosedLoop.ai, which was recognized as the #1 AI Software Solution for Health Care in 2022 and 2023.

Gil Issachar, Chief Technology Officer

Gil Issachar serves as the Chief Technology Officer. He has presented data demonstrating the capability of Firefly's BNA™ system to assess patients' brain age using cognitive data from ERP.

Arun Menawat, Chairman of the Board

Arun Menawat was elected as the new Chairman of the Board in March 2025.

AI Analysis | Feedback

Key Risks to Firefly Neuroscience (AIFF)

The key risks to Firefly Neuroscience (AIFF) primarily revolve around its financial viability, regulatory challenges, and competitive landscape.

Limited Revenue Generation, Profitability, and Cash Burn: Firefly Neuroscience is currently generating minimal revenues and does not anticipate significant revenue until the broad commercialization of its Brain Network Analytics (BNA) Platform. The company has experienced declining earnings over the past five years and generates less than $1 million in revenue. There is no assurance that it will achieve sustained revenues or profitability. Furthermore, the company has been "quickly burning through cash" and its short-term obligations exceed its liquid assets, leading to a cash runway of less than one year. This necessitates raising additional capital, which has led to substantial dilution for existing shareholders in the past year.
Regulatory Hurdles and Market Acceptance for Unproven Business Plan: Operating within the heavily regulated healthcare and biotechnology sectors, Firefly Neuroscience must successfully navigate complex regulatory pathways to bring its products to market. Delays or failures in obtaining necessary approvals could significantly impede growth. The company is in a development stage with no operating history in the broad commercialization of medical devices or platforms for consumer use, and its future relies on an unproven business plan. Even with innovative technologies, market acceptance is not guaranteed, requiring effective demonstration of product efficacy and safety to healthcare providers and patients.
Intense Competition: Firefly Neuroscience faces significant competition from both established companies and emerging startups in the neuroscience market. Major players such as Medtronic, NeuroPace, and Nexstim have strong portfolios and market presence. To succeed, Firefly Neuroscience must differentiate itself through continuous innovation, effective marketing strategies, and strong customer relationships.

AI Analysis | Feedback

null

AI Analysis | Feedback

Firefly Neuroscience (AIFF) focuses on developing Artificial Intelligence (AI) solutions to improve brain health outcomes for patients with neurological and mental disorders. Their primary product is the FDA-510(k) cleared Brain Network Analytics (BNA™) technology, which aids in the diagnosis and treatment monitoring of conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. The company also operates in the areas of cognitive enhancement devices and AI-driven mental health tools. The addressable markets for Firefly Neuroscience's main products and services are as follows:

Neurotechnology Market: The global neurotechnology market is projected to reach $12.6 billion by 2030, with an annual growth rate of 8.3%.
Cognitive Assessment and Training in Healthcare Market: The global cognitive assessment and training in healthcare market was estimated at USD 5.2 billion in 2023 and is projected to reach USD 26.1 billion by 2030. North America held the largest revenue share in this market in 2023.
Brain Health Supplements Market: The global brain health supplements market size was estimated at USD 10.95 billion in 2024 and is projected to reach USD 23.52 billion by 2030. North America dominated the global market with a 39.0% share in 2024.
Attention-Deficit Hyperactivity Disorder (ADHD) Market: The global Attention-Deficit Hyperactivity Disorder (ADHD) Market was valued at USD 18.75 billion in 2024 and is expected to reach USD 32.90 billion by 2032. North America leads this market.
Anxiety Disorders and Depression Treatment Market: The global anxiety disorders and depression treatment market size was estimated at USD 15.42 billion in 2024 and is projected to reach USD 19.28 billion by 2030. North America dominated this market with a 37.6% share in 2024.
Schizophrenia Market: The schizophrenia market across the top 7 major markets (US, EU4, UK, and Japan) reached a value of USD 9,898.3 million in 2024 and is expected to reach USD 15,908.6 million by 2035. The United States represents the largest market for schizophrenia treatment.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Firefly Neuroscience (AIFF)

Commercialization and Adoption of BNA Platform: Firefly Neuroscience is focused on the commercial launch of its FDA-510(k) cleared Brain Network Analytics (BNA) software platform. This includes targeting pharmaceutical companies for drug research and clinical trials, as well as medical practitioners for clinical use.
Strategic Partnerships and Market Expansion for BNA Platform: The company has recently partnered with HealingMaps to provide its cognitive electrophysiology analytics to over 2,500 Ketamine, Psilocybin, and TMS clinics across North America, indicating a significant expansion of its customer base through strategic alliances. Additionally, Firefly has secured other commercial agreements for the use of its BNA platform in precision neuroscience research.
Technological Advancements and New Platform Development: The successful deployment of NVIDIA L40S GPU acceleration to power its next-gen 'CLEAR' platform suggests ongoing innovation. Such technological advancements can lead to enhanced product offerings, attracting more customers, or enabling premium pricing for advanced capabilities.
Acquisition-led Growth: The acquisition of Evoke Neuroscience has been identified as a positive strategic move. Acquisitions typically contribute to revenue growth by expanding market share, product portfolios, and customer bases.
Geographic Market Expansion: Firefly Neuroscience has indicated plans to expand its research partnerships and regulatory engagement into European and Asian markets, moving beyond its initial U.S.-based clinical programs. This international expansion represents a significant opportunity for future revenue growth.

AI Analysis | Feedback

Share Repurchases

Firefly Neuroscience, Inc. has shown a Buyback Cash Coverage ratio of 0.0x and a Buyback Yield LTM of 0.0% for the periods 2023-2024, indicating no significant share repurchases.

Share Issuance

Stockholders approved an increase in authorized shares to 5,001,000,000 (5,000,000,000 common; 1,000,000 preferred) on October 31, 2025, providing flexibility for future financing.
An amendment to the 2024 Long-Term Incentive Plan was approved on October 31, 2025, adding 317,820 shares and adopting an annual evergreen tied to 4% of outstanding shares or a Board-determined lower amount from January 1, 2026, through January 1, 2035.
Stockholder approval was granted on February 14, 2025, for significant stock issuances to Helena Special Opportunities LLC and pursuant to a Purchase Agreement with Arena Business Solutions Global SPC II, Ltd.

Inbound Investments

Institutional investors purchased a total of 94,991 shares, representing approximately $291.24K in transactions, in the 24 months leading up to November 2025.
Noteworthy institutional investors buying shares include Geode Capital Management LLC ($60.95K), Waldron Private Wealth LLC ($32K), FNY Investment Advisers LLC ($22.71K), Trueblood Wealth Management LLC ($16K), and Citadel Advisors LLC ($11.33K).

Outbound Investments

The acquisition of Evoke Neuroscience has been noted as a positive strategic move, though specific dollar amounts for this investment were not available in the provided information.

Capital Expenditures

Capital expenditures reported in recent years include approximately -$148K (likely 2024), -$536K (likely 2022), -$70K (likely 2021), and -$65K (likely 2020).
The company has historically invested significantly in developing its Brain Network Analytics (BNA) software, compiling a database of brain wave tests, and securing patent protection.
Recent capital allocation has focused on technological advancements, such as the successful deployment of NVIDIA L40S GPU Acceleration to power its next-gen 'CLEAR' Platform in August 2025.

	Best Bets In Information Technology Sector
What You Pay
P/E	-0.7	28.3	17.1	46.3	44.4	29.9	16.4	14.6	19.2	24.1	21.0
P/EBIT	-0.7	20.4	13.8	39.4	37.9	10.6	23.9	11.9	20.9	66.0	24.0
What You Get
Rev Chg Q	1,075.8%	7.3%	28.0%	62.5%	22.7%	25.3%	4.4%	-0.7%	15.5%	18.9%	63.0%
Rev Chg LTM	958.1%	5.5%	28.8%	65.2%	31.0%	16.2%	3.8%	-0.4%	17.8%	30.5%	53.8%
Rev Chg 3Y Avg	�	5.2%	27.1%	91.6%	17.3%	16.5%	3.4%	3.4%	31.0%	17.2%	38.6%
FCF/Rev 3Y Avg	�	57.4%	54.2%	43.4%	39.3%	36.7%	36.1%	33.4%	32.5%	28.6%	26.0%

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Firefly Neuroscience Earnings Notes
2	Can Firefly Neuroscience Stock Recover If Markets Fall?	Return

	Title
0	ARTICLES

Trade Ideas

Select ideas related to AIFF. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ENPH_11302025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11302025	ENPH	Enphase Energy	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	11.7%	11.7%	-0.9%
PD_11262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11262025	PD	PagerDuty	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	10.2%	10.2%	0.0%
CRM_11212025_Dip_Buyer_FCFYield	11212025	CRM	Salesforce	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.2%	16.2%	-0.1%
HUBS_11212025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11212025	HUBS	HubSpot	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	11.7%	11.7%	0.0%
FIVN_11212025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11212025	FIVN	Five9	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	4.2%	4.2%	0.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OMER	Omeros	0.9	75.5%	55.5%
DVAX	Dynavax Technologies	1.8	38.2%	20.4%
EWTX	Edgewise Therapeutics	2.9	25.5%	2.2%
AGIO	Agios Pharmaceuticals	1.7	18.6%	-11.2%
TVTX	Travere Therapeutics	3.6	13.9%	131.2%
KOD	Kodiak Sciences	1.6	13.2%	212.4%
RZLT	Rezolute	0.3	13.2%	-44.1%
UP	Wheels Up Experience	0.5	11.7%	-57.4%
FBYD	Falcons Beyond Global	0.7	9.5%	129.7%
BW	Babcock & Wilcox Enterprises	0.5	8.5%	226.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ASTS	AST SpaceMobile	18.9	-8.9%	269.9%
QBTS	D-Wave Quantum	9.4	-5.5%	227.6%
NNE	Nano Nuclear Energy	1.2	-4.6%	21.7%
MNMD	Mind Medicine	1.2	-4.2%	93.0%
PPTA	Perpetua Resources	2.0	-4.0%	149.1%
KOS	Kosmos Energy	0.4	-4.0%	-73.6%
FRMI	Fermi	5.5	-4.0%	-75.7%
EXOD	Exodus Movement	0.4	-3.9%	-50.5%
TLRY	Tilray Brands	10.8	-3.6%	-23.7%
AEHR	Aehr Test Systems	0.7	-3.1%	32.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	74.0%	55.5%
LUNR	Intuitive Machines	2.0	63.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	51.1%	11.2%
FBYD	Falcons Beyond Global	0.7	47.2%	129.7%
FLY	Firefly Aerospace	3.8	45.9%	-55.2%
RKLB	Rocket Lab	39.8	43.0%	203.0%
DVAX	Dynavax Technologies	1.8	42.5%	20.4%
UAMY	United States Antimony	0.8	39.9%	258.8%
DJT	Trump Media & Technology	4.0	36.7%	-58.0%
RZLT	Rezolute	0.3	36.3%	-44.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	31.7	-80.5%	-28.0%
TPL	Texas Pacific Land	6.8	-66.5%	-19.2%
LW	Lamb Weston	6.0	-28.6%	-34.8%
TLRY	Tilray Brands	10.8	-21.2%	-23.7%
INSP	Inspire Medical Systems	2.8	-19.1%	-48.4%
TDUP	ThredUp	0.8	-17.1%	354.7%
OLMA	Olema Pharmaceuticals	2.3	-15.8%	370.8%
IIPR	Innovative Industrial Properties	1.4	-12.9%	-15.7%
ABM	ABM Industries	2.6	-12.6%	-15.8%
FRMI	Fermi	5.5	-12.6%	-75.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	3.0	144.6%	47.5%
TE	T1 Energy	1.1	124.5%	418.4%
ANF	Abercrombie & Fitch	6.0	93.2%	-15.2%
VERA	Vera Therapeutics	3.6	90.4%	31.6%
LUNR	Intuitive Machines	2.0	85.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	82.5%	11.2%
RKLB	Rocket Lab	39.8	81.8%	203.0%
PL	Planet Labs PBC	6.2	76.1%	403.0%
NRGV	Energy Vault	0.8	66.9%	118.9%
FLY	Firefly Aerospace	3.8	60.4%	-55.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-44.1%
JANX	Janux Therapeutics	0.9	-54.6%	-73.3%
LENZ	LENZ Therapeutics	0.5	-46.3%	-40.6%
FRMI	Fermi	5.5	-45.2%	-75.7%
GOGO	Gogo	0.6	-34.1%	-43.0%
HPK	HighPeak Energy	0.6	-30.8%	-69.2%
ORIC	ORIC Pharmaceuticals	0.7	-28.5%	4.5%
FDMT	4D Molecular Therapeutics	0.5	-25.6%	45.4%
NKTR	Nektar Therapeutics	0.6	-25.1%	215.0%
LW	Lamb Weston	6.0	-24.8%	-34.8%

Peer Comparisons for Firefly Neuroscience

Peers to compare with:

Financials

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Mkt Price	1.11	21.41	0.77	1.43	16.19	63.13	8.81
Mkt Cap	0.0	0.8	0.0	0.1	0.5	3.4	0.3
Rev LTM	1	83	9	130	95	1,349	89
Op Inc LTM	-9	-57	-4	-38	-18	194	-13
FCF LTM	-8	-41	-3	-31	-17	191	-12
FCF 3Y Avg	-	-	-9	-31	-19	103	-14
CFO LTM	-8	-40	-3	-30	-16	251	-12
CFO 3Y Avg	-	-	-9	-29	-19	150	-14

Growth & Margins

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Rev Chg LTM	958.1%	37.9%	163.5%	78.6%	24.1%	8.6%	58.3%
Rev Chg 3Y Avg	-	-	427.0%	31.8%	29.6%	9.9%	30.7%
Rev Chg Q	1,075.8%	31.4%	906.6%	101.3%	29.9%	12.5%	66.3%
QoQ Delta Rev Chg LTM	82.9%	7.0%	37.2%	16.9%	7.1%	3.0%	12.0%
Op Mgn LTM	-1,119.4%	-68.5%	-46.5%	-29.2%	-19.2%	14.4%	-37.8%
Op Mgn 3Y Avg	-	-	-334.3%	-38.6%	-34.2%	8.3%	-36.4%
QoQ Delta Op Mgn LTM	1,340.6%	-1.3%	39.1%	5.3%	3.2%	1.0%	4.3%
CFO/Rev LTM	-971.5%	-48.3%	-31.2%	-23.0%	-17.2%	18.6%	-27.1%
CFO/Rev 3Y Avg	-	-	-336.7%	-34.9%	-26.3%	11.6%	-30.6%
FCF/Rev LTM	-984.9%	-49.5%	-32.1%	-23.5%	-17.5%	14.2%	-27.8%
FCF/Rev 3Y Avg	-	-	-344.7%	-37.1%	-26.7%	7.9%	-31.9%

Valuation

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Mkt Cap	0.0	0.8	0.0	0.1	0.5	3.4	0.3
P/S	19.1	9.5	4.3	0.7	5.7	2.6	5.0
P/EBIT	-0.7	-15.6	-11.8	-2.6	-33.7	-25.0	-13.7
P/E	-0.7	-15.0	-10.7	-2.2	-22.4	-15.9	-12.9
P/CFO	-2.0	-19.7	-13.7	-3.2	-32.9	13.8	-8.4
Total Yield	-142.7%	-6.7%	-9.4%	-46.6%	-4.5%	-6.3%	-8.0%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-	-	-37.1%	-71.8%	-7.6%	3.6%	-22.3%
D/E	0.0	0.0	0.0	0.9	0.1	0.1	0.1
Net D/E	-0.3	-0.2	-0.2	0.7	0.0	-0.0	-0.1

Returns

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
1M Rtn	-31.1%	33.8%	15.9%	12.2%	-0.4%	4.4%	8.3%
3M Rtn	-62.4%	75.4%	-18.1%	-48.9%	58.4%	18.6%	0.3%
6M Rtn	-60.6%	10.8%	6.1%	-58.3%	53.2%	37.6%	8.5%
12M Rtn	-56.3%	-20.6%	0.0%	-2.4%	45.3%	35.0%	-1.2%
3Y Rtn	-93.7%	-	-50.0%	-76.1%	1,090.4%	17.6%	-50.0%
1M Excs Rtn	-34.5%	30.4%	12.5%	8.8%	-3.8%	1.0%	4.9%
3M Excs Rtn	-66.6%	84.6%	-19.3%	-51.6%	56.8%	15.8%	-1.8%
6M Excs Rtn	-75.0%	-1.9%	-7.5%	-71.0%	35.1%	24.9%	-4.7%
12M Excs Rtn	-69.4%	-37.3%	-15.4%	-14.4%	23.5%	15.8%	-14.9%
3Y Excs Rtn	-174.7%	-	-147.5%	-158.6%	883.6%	-64.8%	-147.5%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	11/12/2025	4/3/2025	4/3/2025	2/2/2024	2/2/2024
Key Financials
Total Revenue	1	0	0	0	0
EBITDA	-21	-10	-3	-3	-4
Operating Income	-9	-9	-3	-3	-5
Net Income	-21	-10	-3	-4	-4
EPS	-2.53	-1.60	-0.50	-0.73	-0.84
Growth Rates
Total Revenue Growth	958.1%	-78.3%	∞%	-100.0%	-
EBITDA Growth	-170.3%	-299.5%	19.3%	16.1%	-
Operating Income Growth	-7.1%	-198.2%	5.4%	29.6%	-
Net Income Growth	-173.3%	-301.8%	31.3%	13.5%	-
Margins
EBITDA Margin	-2658.5%	-9557.4%	-518.9%	-	-11928.1%
Operating Income Margin	-1119.4%	-8500.0%	-618.1%	-	-14437.5%
Net Income Margin	-2705.9%	-9685.2%	-522.7%	-	-13690.6%
Cash & Debt
Total Cash	4	2	2	0	1
Total Debt	0	1	0	0	2
Net Debt / (Cash)	-4	-1	-2	-0	1
Cash Flows
Net Cash from Operations	-8	-6	-2	-3	-4
Free Cash from Operations	-8	-7	-3	-3	-4
Returns to Shareholders
Dividends	0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	11/12/2025	8/13/2025	5/14/2025	4/3/2025	11/14/2024	8/19/2024	5/14/2025	4/3/2025	2/2/2024	8/19/2024
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	2
Ebitda	-3	-2	-13	-4	-4	-1	-1	-1	-1	1
Operating Income	-3	-2	-2	-3	-4	-1	-1	-2	-1	-1
Net Income	-3	-2	-13	-4	-4	-1	-1	-1	-1	0
EPS	-0.20	-0.14	-1.74	-0.45	-0.61	-0.16	-0.22	-0.21	-0.13	0.05
Key Financials TTM
Total Revenue TTM	1	0	0	0	0	0	2	2	-	-
Ebitda TTM	-21	-23	-22	-10	-8	-4	-2	-2	-	-
Operating Income TTM	-9	-11	-10	-9	-8	-5	-4	-4	-	-
Net Income TTM	-21	-23	-22	-10	-8	-4	-3	-2	-	-
Growth Rates Quarterly
Total Revenue Growth	1075.8%	2890.0%	258.3%	178.9%	43.5%	-99.5%	-	-	-	-
EBITDA Growth	39.7%	-41.7%	-1041.3%	-244.6%	-558.6%	-328.6%	-48.5%	-	-	-
Operating Income Growth	41.3%	-29.8%	-89.3%	-63.5%	-559.7%	-105.3%	-43.6%	-	-	-
Net Income Growth	38.5%	-45.0%	-1052.4%	-251.4%	-559.8%	-638.4%	-39.9%	-	-	-
Margins Quarterly
EBITDA Margin	-662.6%	-592.3%	-29727.9%	-6964.2%	-12912.1%	-12500.0%	-9333.3%	-5636.8%	-2813.0%	27.0%
Operating Income Margin	-645.4%	-546.5%	-4802.3%	-4834.0%	-12933.3%	-12590.0%	-9091.7%	-8247.4%	-2813.0%	-30.3%
Net Income Margin	-680.2%	-613.0%	-30069.8%	-7141.5%	-12997.0%	-12640.0%	-9350.0%	-5668.4%	-2826.1%	11.6%
Cash & Debt
Total Cash	4	6	10	2	1	0	-	2	1	-
Total Debt	0	0	0	1	0	0	0	0	0	0
Net Debt / (Cash)	-4	-6	-10	-1	-1	0	-	-2	-1	-
Cash Flows Quarterly
FCF from Operations	-1	-2	-3	-1	-3	-1	-1	-1	0	-
Cash Flows TTM
FCF from Operations TTM	-8	-9	-7	-6	-5	-2	-	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-8.8%	-5.8%	-8.3%	-12.0%	-20.1%	-14.5%	-	-8.4%	-3.5%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-7.7%	-9.4%	-10.1%	-10.7%	-9.6%	-13.1%	-	-4.8%	-	-

Segment Financials

Revenue by Segment

$ Mil	2024
Analytical reports	0
Service	0
Total	0

Price Behavior

Price Behavior

Market Price	$1.10
Market Cap ($ Bil)	0.0
First Trading Date	01/03/2007
Distance from 52W High	-92.9%
	50 Days	200 Days
DMA Price	$1.73	$2.77
DMA Trend	down	down
Distance from DMA	-36.4%	-60.4%
	3M	1YR
Volatility	73.5%	216.6%
Downside Capture	571.99	322.93
Upside Capture	2.10	195.48
Correlation (SPY)	43.5%	15.6%

AIFF Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.65	2.76	2.51	2.67	1.74	1.30
Up Beta	-0.21	0.19	0.79	1.91	0.67	0.71
Down Beta	1.53	2.11	3.43	3.62	1.39	1.33
Up Capture	289%	136%	94%	121%	504%	82%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	10	17	29	60	111	340
Down Capture	379%	429%	329%	288%	161%	111%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	22	30	60	129	394

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of AIFF With Other Asset Classes (Last 1Y)
	AIFF	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-54.2%	26.7%	19.2%	71.9%	8.9%	6.0%	-10.4%
Annualized Volatility	215.4%	27.6%	19.5%	19.3%	15.3%	17.1%	35.0%
Sharpe Ratio	0.31	0.84	0.78	2.69	0.36	0.18	-0.12
Correlation With Other Assets		14.8%	15.4%	4.6%	9.7%	13.4%	14.4%

ETFs used for asset classes: Sector ETF = XLK, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of AIFF With Other Asset Classes (Last 5Y)
	AIFF	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-50.1%	19.0%	14.9%	18.7%	11.7%	4.8%	32.6%
Annualized Volatility	158.2%	24.7%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	0.18	0.69	0.70	0.97	0.51	0.17	0.59
Correlation With Other Assets		9.7%	11.9%	3.4%	3.3%	11.7%	4.0%

Based On 10-Year Data

		Comparison of AIFF With Other Asset Classes (Last 10Y)
	AIFF	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-11.9%	22.3%	14.7%	14.9%	6.9%	5.2%	69.2%
Annualized Volatility	173.3%	24.2%	18.0%	14.8%	17.6%	20.8%	55.8%
Sharpe Ratio	0.62	0.84	0.70	0.83	0.31	0.22	0.90
Correlation With Other Assets		8.0%	9.4%	4.2%	3.3%	8.7%	4.1%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	485,452
Short Interest: % Change Since 11302025	1.4%
Average Daily Volume	116,998
Days-to-Cover Short Interest	4.15
Basic Shares Quantity	13,497,668
Short % of Basic Shares	3.6%

Returns Analyses

	Title
0	Can Firefly Neuroscience Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/15/2024	-5.7%	-5.7%	-13.2%
11/21/2022	-21.1%	-28.2%	-44.7%
8/15/2022	9.1%	11.6%	-4.1%
4/18/2022	5.0%	1.3%	-35.4%
11/3/2021	-9.5%	-13.8%	-9.7%
8/18/2021	-3.8%	3.8%	15.0%
5/18/2021	-2.6%	7.7%	31.9%
2/17/2021	17.6%	4.0%	45.7%
...
SUMMARY STATS
# Positive	5	7	5
# Negative	5	3	5
Median Positive	9.1%	7.7%	45.7%
Median Negative	-5.7%	-13.8%	-13.2%
Max Positive	51.5%	27.3%	106.1%
Max Negative	-21.1%	-28.2%	-44.7%

	Forward Returns
11/15/2024	-5.7%	-5.7%	-13.2%
11/21/2022	-21.1%	-28.2%	-44.7%
8/15/2022	9.1%	11.6%	-4.1%
4/18/2022	5.0%	1.3%	-35.4%
11/3/2021	-9.5%	-13.8%	-9.7%
8/18/2021	-3.8%	3.8%	15.0%
5/18/2021	-2.6%	7.7%	31.9%
2/17/2021	17.6%	4.0%	45.7%
11/16/2020	6.3%	26.6%	50.6%
8/18/2020	51.5%	27.3%	106.1%
SUMMARY STATS
# Positive	5	7	5
# Negative	5	3	5
Median Positive	9.1%	7.7%	45.7%
Median Negative	-5.7%	-13.8%	-13.2%
Max Positive	51.5%	27.3%	106.1%
Max Negative	-21.1%	-28.2%	-44.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11122025	10-Q 9/30/2025
6302025	8132025	10-Q 6/30/2025
3312025	5142025	10-Q 3/31/2025
12312024	4032025	10-K 12/31/2024
9302024	11142024	10-Q 9/30/2024
6302024	8192024	10-Q 6/30/2024
12312022	2022024	S-4/A 12/31/2022

Insider Activity

Expand for More

	Owner	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Windsor Private Capital LP	10222025	Sell	2.46	33,500	82,310	3,277,702	Form
1	Windsor Private Capital LP	10172025	Sell	2.74	17,500	48,027	3,986,793	Form
2	Windsor Private Capital LP	10142025	Sell	2.94	30,126	88,694	4,730,129	Form

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Firefly Neuroscience (AIFF)

Market Price (12/24/2025): $1.19 | Market Cap: $16.1 MilSector: Information Technology | Industry: Application Software

Firefly Neuroscience (AIFF)

Market Price (12/24/2025): $1.19Market Cap: $16.1 MilSector: Information TechnologyIndustry: Application Software

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

AIFF Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Firefly Neuroscience (AIFF)

Key Risks to Firefly Neuroscience (AIFF)

Expected Drivers of Future Revenue Growth for Firefly Neuroscience (AIFF)

Share Repurchases

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Firefly Neuroscience (AIFF)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Firefly Neuroscience

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/24/2025): $1.19 | Market Cap: $16.1 Mil
Sector: Information Technology | Industry: Application Software

Market Price (12/24/2025): $1.19
Market Cap: $16.1 Mil
Sector: Information Technology
Industry: Application Software